Bioinformatics Support the Possible Triggering of Autoimmune Thyroid Diseases by Yersinia enterocolitica Outer Membrane Proteins Homologous to the Human Thyrotropin Receptor

Thyroid ◽  
2011 ◽  
Vol 21 (11) ◽  
pp. 1283-1284 ◽  
Author(s):  
Fabrizio Guarneri ◽  
Dario Carlotta ◽  
Giovanna Saraceno ◽  
Francesco Trimarchi ◽  
Salvatore Benvenga
Author(s):  
Junji Konishi ◽  
Yasuhiro Iida ◽  
Takashi Misaki ◽  
Keigo Endo ◽  
Kanji Torizuka ◽  
...  

1988 ◽  
Vol 119 (1) ◽  
pp. 81-84 ◽  
Author(s):  
Rauli Leino ◽  
Riitta Lahesmaa-Rantala ◽  
Kaisa Granfors ◽  
Auli Toivanen

Abstract. IgM, IgG and IgA class serum antibodies against Yersinia enterocolitica O:3 and O:9 and Yersinia pseudotuberculosis la and 3 in 41 patients with thyroid disease and 50 healthy control persons were measured by enzyme-linked immunosorbent assay (ELISA). Concentrations of antibody levels against Yersinia enterocolitica O:9 and Yercinia pseudotuberculosis la and 3 did not differ significantly between the patients and controls. The median value of IgA class antibody Yersinia enterocolitica O:3 was 7.5 relative units (EIU, percentage of the reference serum) in the patients with thyroid disease and 0.7 EIU in the controls (P<0.01; Mann-Whitney's U-test), whereas IgM and IgG class antibodies did not show this difference. IgA class serum antibodies were especially high in patients with autoimmune thyroid diseases. These findings and two case reports support the concept that there may be a causal relationship between infections with Yersinia enterocolitica O:3 and autoimmune thyroid diseases.


1994 ◽  
Vol 131 (4) ◽  
pp. 359-368 ◽  
Author(s):  
Yi Zhu ◽  
Luc Portmann ◽  
Nicole Dénéréaz ◽  
Thérèse Lemarchand-Béraud

Zhu Y, Portmann L, Dénéréaz N. Lemarchand-Béraud T. Simultaneous assay for three types of thyrotropin receptor antibody activites using FRTL-5 cells in patients with autoimmune thyroid diseases. Eur J Endocrinol 1994;131:359–68. ISSN 0804–4643 The relationships between the different circulating thyrotropin receptor antibodies (TSH-R-abs) in autoimmune thyroid disease (AITD) are complex. In order to investigate them, we have developed an assay for the simultaneous measurement of three types of TSH-R-abs: TSH-binding inhibiting immunoglobulin (TBII); thyroid-stimulating antibody (TS-ab) and TSH-stimulation blocking antibody (TSB-ab). A large number of patients with Graves' disease (GD)—untreated and treated—Hashimoto's thyroiditis (HT), primary myxedema (PM) and non-immune goiter (NIG) were investigated. In untreated Graves' patients the frequency of positive TS-ab and TBII sera was found to be 90 and 69%, respectively, the presence of TS-ab and/or TBII being detected in 98%. After long-term antithyroid treatment administered to GD patients, the frequency of positivity of both TBII and TSab was decreased, whether hyperthyroidism was cured or not. The TSB-ab was detected in the serum of 8% of patients with GD, and the frequency of TSB-ab did not increase following treatment and alteration in thyroid function. No significant correlation was found between TSB-ab and thyroid function in Graves' patients. Besides, we found that all the GD patients presenting positive TSB-ab were also TBII positive. A follow-up study of the three TSH-R-abs was performed in 35 patients with GD during a mean of 14.3 ± 8.5 months (4–34 months) of antithyroid drug treatment. Ten out of 24 patients (42%) with positive TBII and 16 out of 32 (50%) with positive TS-ab turned from positive to negative during the time of follow-up. Regarding relapse in hyperthyroid GD, we found that TS-ab was positive in 80% and TBII was positive in 40% of the patients with Graves' relapse, indicating that the presence of TS-ab is a better index for relapse prediction in Graves' hyperthyroidism than TBII. The TSB-ab was found with higher frequency in HT and PM than in GD, i.e. 21%, 18% and 8%, respectively. The TSB-ab positivity was correlated significantly with TBII in our patients with AITD when TSB-ab was positive. This new simultaneous assay of the three TSH-R-abs should be very helpful for further investigation of the autoimmune aspects of AITD and it should help us to progress in a better understanding of the pathogeny of the different AITDs. Thérèse Lemarchand-Béraud, Division of Endocrinology and Metabolism, University Hospital (CHUV), CH-1011 Lausanne, Switzerland


Sign in / Sign up

Export Citation Format

Share Document